Millennium HealthCare Inc. Continues Customer Growth; Revenues Could Exceed $150,000,000 With Addition of New Network Selling Agreement

Contract Includes Minimum Usage Metrics

Mar 10, 2014, 08:30 ET from Millennium HealthCare Inc.

GARDEN CITY, N.Y., March 10, 2014 /PRNewswire/ -- Millennium HealthCare Inc. (OTCBB: MHCC) today announced that its subsidiary, Millennium Medical Devices LLC, has signed a network selling agreement with another US based healthcare organization for the use of its medical devices in 100 of the organization's locations.  This agreement includes an average monthly minimum use of 350 units, per device, per location.  This new agreement combined with the agreement as reported in the Company's February 27th press release will bring the total number of contracted locations to 300.

The network selling agreement includes the use of the Company's exclusive distribution rights for the VasoScan cardiovascular assessment test device.   VasoScan is an FDA cleared, non-invasive device that provides a reproducible assessment of arterial elasticity and stiffness which determines plaque levels in the arterial walls. Plaque buildup in the arteries can cause cardiovascular disease and inhibit blood flow to major organs causing heart attack and stroke. Millennium Medical Devices maintains the exclusive rights to market and distribute the VasoScan device in the United States.

The network selling agreement also includes the use of the Company's exclusive distribution rights for the OralCDx Brush Biopsy Test Kit. OralCDx is a non-invasive test that is used to test the small white and red tissue spots commonly found in the mouth to rule out precancerous change. According to the oral cancer foundation, close to 42,000 Americans will be diagnosed with oral and oropharyngeal cancers this year. This disease will cause over 8,000 deaths. The test has previously been available to dentists nationwide, and has already resulted in the prevention of thousands of oral cancers. Through the exclusive distribution agreement with Millennium Medical Devices, primary care physicians will now be able to easily administer this test to their patients.

"Being able to detect disease for early intervention could potentially help the over 800,000 people who die annually from cardiovascular disease in the United States alone (according to the CDC)" said Dominick Sartorio, CEO of Millennium.

"There are over 250,000 primary care physicians in the United States who could utilize these tests in their practices.  We anticipate that a majority of the now 300 locations under contract should be operational within the next 12 months as we continue to introduce VasoScan and Oral CDx as quickly as we can, utilizing the contracted model. We feel that this sales model can assist investors in easily understanding the opportunities we have through these exclusive distribution relationships. Based on the minimum contracted amounts within this these two network agreements, Millennium can be in a position to potentially exceed $150,000,000 in revenues annually."

About Millennium HealthCare Inc.

Millennium HealthCare Inc. through its wholly owned operating subsidiaries provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services and practice development and management services.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995   

This press release contains certain statements that may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

SOURCE Millennium HealthCare Inc.